$2.3 Billion is the total value of Camber Capital Management LP's 40 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 45.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VTRS | VIATRIS INC | $240,810,000 | -3.8% | 23,000,000 | 0.0% | 10.45% | +15.4% | |
| SNY | SANOFIsponsored adr | $200,120,000 | -2.6% | 4,000,000 | 0.0% | 8.68% | +16.9% | |
| ZBH | ZIMMER BIOMET HOLDINGS INC | $141,831,000 | -17.9% | 1,350,000 | 0.0% | 6.15% | -1.5% | |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $138,676,000 | +29.1% | 1,850,000 | +34.5% | 6.02% | +54.9% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $124,305,000 | +24.0% | 1,500,000 | +15.4% | 5.39% | +48.7% |
| PRGO | Buy | PERRIGO CO PLC | $111,568,000 | +16.1% | 2,750,000 | +10.0% | 4.84% | +39.3% |
| WBA | Buy | WALGREENS BOOTS ALLIANCE INC | $107,068,000 | -0.4% | 2,825,000 | +17.7% | 4.64% | +19.5% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $99,954,000 | -10.0% | 2,700,000 | -10.0% | 4.34% | +7.9% |
| PTCT | Buy | PTC THERAPEUTICS INC | $98,147,000 | +50.3% | 2,450,000 | +40.0% | 4.26% | +80.3% |
| SEM | Buy | SELECT MED HLDGS CORP | $94,480,000 | +293.8% | 4,000,000 | +300.0% | 4.10% | +372.2% |
| INCY | Sell | INCYTE CORP | $91,164,000 | -15.0% | 1,200,000 | -11.1% | 3.96% | +2.0% |
| MYGN | Buy | MYRIAD GENETICS INC | $90,850,000 | +3.0% | 5,000,000 | +42.9% | 3.94% | +23.6% |
| THC | Buy | TENET HEALTHCARE CORP | $86,724,000 | +49.5% | 1,650,000 | +144.4% | 3.76% | +79.3% |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $75,029,000 | -67.6% | 745,000 | -53.4% | 3.26% | -61.2% |
| BKD | BROOKDALE SR LIVING INC | $72,640,000 | -35.6% | 16,000,000 | 0.0% | 3.15% | -22.7% | |
| CHNG | Sell | CHANGE HEALTHCARE INC | $53,615,000 | -59.0% | 2,325,000 | -61.2% | 2.33% | -50.8% |
| RETA | REATA PHARMACEUTICALS INCcl a | $45,585,000 | -7.2% | 1,500,000 | 0.0% | 1.98% | +11.2% | |
| XRAY | New | DENTSPLY SIRONA INC | $44,663,000 | – | 1,250,000 | +100.0% | 1.94% | – |
| MRTX | Sell | MIRATI THERAPEUTICS INC | $43,635,000 | -55.8% | 650,000 | -45.8% | 1.89% | -47.0% |
| EXEL | Buy | EXELIXIS INC | $34,353,000 | +405.1% | 1,650,000 | +450.0% | 1.49% | +505.7% |
| ZIMVIE INC | $32,020,000 | -29.9% | 2,000,000 | 0.0% | 1.39% | -15.9% | ||
| EVH | Buy | EVOLENT HEALTH INCcl a | $30,710,000 | +412.9% | 1,000,000 | +439.4% | 1.33% | +513.8% |
| BIIB | New | BIOGEN INC | $25,493,000 | – | 125,000 | +100.0% | 1.11% | – |
| NUVA | NUVASIVE INC | $24,580,000 | -13.3% | 500,000 | 0.0% | 1.07% | +4.0% | |
| ALGN | New | ALIGN TECHNOLOGY INC | $23,667,000 | – | 100,000 | +100.0% | 1.03% | – |
| TEVA | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $20,680,000 | -19.9% | 2,750,000 | 0.0% | 0.90% | -4.0% | |
| INGN | Buy | INOGEN INC | $19,949,000 | -18.0% | 825,000 | +10.0% | 0.87% | -1.6% |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $18,606,000 | -13.0% | 1,050,000 | 0.0% | 0.81% | +4.4% | |
| QTRX | New | QUANTERIX CORP | $18,484,000 | – | 1,141,700 | +100.0% | 0.80% | – |
| CSII | New | CARDIOVASCULAR SYS INC DEL | $13,504,000 | – | 940,400 | +100.0% | 0.59% | – |
| CANO | New | CANO HEALTH INC | $13,140,000 | – | 3,000,000 | +100.0% | 0.57% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $12,070,000 | +4.8% | 4,235,000 | +5.9% | 0.52% | +25.7% |
| EXAS | New | EXACT SCIENCES CORP | $11,817,000 | – | 300,000 | +100.0% | 0.51% | – |
| OSUR | ORASURE TECHNOLOGIES INC | $11,518,000 | -60.0% | 4,250,000 | 0.0% | 0.50% | -52.0% | |
| NSTG | New | NANOSTRING TECHNOLOGIES INC | $10,795,000 | – | 850,000 | +100.0% | 0.47% | – |
| ZYME | ZYMEWORKS INC | $10,600,000 | -19.1% | 2,000,000 | 0.0% | 0.46% | -3.0% | |
| GKOS | GLAUKOS CORP | $8,495,000 | -21.4% | 187,022 | 0.0% | 0.37% | -5.6% | |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $1,877,000 | – | 424,600 | +100.0% | 0.08% | – |
| SDC | SMILEDIRECTCLUB INC | $1,040,000 | -59.8% | 1,000,000 | 0.0% | 0.04% | -52.1% | |
| New | 2SEVENTY BIO INC | $642,000 | – | 48,600 | +100.0% | 0.03% | – | |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -262,900 | -100.0% | -0.08% | – |
| NKTR | Exit | NEKTAR THERAPEUTICS | $0 | – | -4,000,000 | -100.0% | -0.78% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -300,000 | -100.0% | -1.02% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -1,000,000 | -100.0% | -1.58% | – |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -500,000 | -100.0% | -2.01% | – |
| MRK | Exit | MERCK & CO INC | $0 | – | -1,500,000 | -100.0% | -4.45% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -2,500,000 | -100.0% | -5.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.